Search results for: Anti human Antithrombin
#34287985 2021/07/20 To Up
"Synthesis of coagulation factors during long-term ex situ liver perfusion".Robust viability assessment of grafts during normothermic liver perfusion is a prerequisite for organ use. Coagulation parameters are used commonly for liver assessment in patients. However, they are not yet included in viability assessment during ex situ perfusion. In this study, we analysed coagulation parameters during one week ex situ perfusion at 34 Â°C. Eight discarded human livers were perfused with blood-based, heparinised perfusate for one week; perfusions in a further four livers were terminated on day 4 due to massive ongoing cell death. Coagulation parameters were well below the physiologic range at perfusion start. Physiologic levels were achieved within the first two perfusion days for factor V (68.5 Â± 35.5%), factor VII (83.5 Â± 26.2%), fibrinogen (2.1 Â± 0.4 g/l) and antithrombin (107 Â± 26.5%) in the livers perfused for one week. Despite the increased production of coagulation factors, INR was detectable only at 24h of perfusion (2.1 Â± 0.3) and prolonged thereafter (INR > 9). The prolongation of INR was related to the high heparin level in the perfusate (anti-FXa > 3 U/ml). Intriguingly, livers with ongoing massive cell death also disclosed synthesis of factor V and improved INR. In summary, perfused livers were able to produce coagulation factors at a physiological level ex situ. We propose that single coagulation factor analysis is more reliable for assessing the synthetic function of perfused livers as compared to INR when using a heparinised perfusate.
Dilmurodjon Eshmuminov, Max Hefti, Matteo Mueller, Martin J Schuler, Lucia Bautista Borrego, Marcel AndrÃ© Schneider, Karin Koch, Miriam Weisskopf, Mark W Tibbitt, Philipp Dutkowski, Philipp Rudolf von Rohr, Jan-Dirk Studt, Dustin Becker, Pierre-Alain Clavien
2485 related Products with: "Synthesis of coagulation factors during long-term ex situ liver perfusion".100ug0.1mg1.00 flask1.00 flask100ug100 μg0.25mg100 μg
#34213123 // To Up
[Determination of the anticoagulant activity of low molecular weight heparins by micellar electrokinetic chromatography combined with on-column enzymatic reaction].Low molecular weight heparins (LMWHs) have largely replaced heparin for the treatment and prevention of thrombosis because of their various advantages over unfractionated heparins (UFHs) such as less bleeding, greater bioavailability, and more predictable anticoagulant effects. For special groups of patients, such as pregnant women, children, and patients with renal failure, it is necessary to monitor the anticoagulant activity of LMWHs in the blood. The traditional method used to determine the anticoagulant activity of heparin is the coagulation test. However, the results are various from different laboratories and different reagents. In contrast, the chromogenic substrate method is more accurate, sensitive and is easy to automate. Here, a method for the determination of the anticoagulant activity of LMWHs was developed by using a capillary-electrophoresis-based substrate chromogenic method. In this method, micellar electrokinetic chromatography (MEKC) was used in combination with electrophoretically mediated microanalysis to determine the anti-factor Xa (FXa) activity of LMWHs. The inhibition was measured by employing a chromogenic peptide substrate (CPS) with a -nitroaniline (-NA) moiety as the chromophore. The injection end of the capillary was used as a microreactor in which solutions of LMWHs, antithrombin â ¢ (ATâ ¢), FXa and CPS were successively injected and mixed by using diffusion, the transverse diffusion of laminar flow profiles and applied voltage. The reaction product -NA was separated from unreacted CPS and sample matrix by using the MEKC mode with discontinuous background electrolyte system. The produced -NA was baseline separated from the other components and detected at 380 nm to obtain maximum sensitivity. The amount of -NA was inversely proportional to the activity of LMWHs in the sample. To improve the accuracy of quantification and the method repeatability of methods, nitrofurantoin (NF) was selected as the internal standard, which was added to the solution of CPS. The method was validated and used to measure a set of samples. The method is characterized by automation, good repeatability, high sensitivity, and cost-effectiveness. Additionally, the method does not interfere by the sample matrix, and thus can be used to monitor the anticoagulant activity of LMWHs in plasma.
Mingyu Zhang, Jingwu Kang
1570 related Products with: [Determination of the anticoagulant activity of low molecular weight heparins by micellar electrokinetic chromatography combined with on-column enzymatic reaction].50 ug10 ug400Tests 2 ml Ready-to-use 100tests100tests 5 G 25 ml Ready-to-use 250 g 100 UG 6 ml Ready-to-use 100tests
#34199189 2021/06/13 To Up
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naÃ¯ve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22-92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms ( < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients' clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.
Giuseppe Gallelli, Giulio Di Mizio, Caterina Palleria, Antonio Siniscalchi, Paolo Rubino, Lucia Muraca, Erika Cione, Monica Salerno, Giovambattista De Sarro, Luca Gallelli
2680 related Products with: Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.500 tests25500 tests500 tests500 tests25500 tests500 tests96 tests
#34167310 // To Up
Hereditary antithrombin deficiency in pregnancy - severe thrombophilic disorder as a danger for mother and foetusIn the article, we remember the role of antithrombin (AT) in hemostasis, escalation of AT-potential with heparin and difficulties with monitoring the effectiveness of LMWH therapy (low molecular weight heparin) in patients with AT deficiency. We pay most of our attention to hereditary AT deficiency and its thromboembolic risk in pregnancy.
ÄÃ¡povÃ¡ Irena, Salaj Peter, HrachovinovÃ¡ Ingrid
2652 related Products with: Hereditary antithrombin deficiency in pregnancy - severe thrombophilic disorder as a danger for mother and foetus1 kit100 assays1 kit96 assays 20 400Tests96 samples100 assays24 tests100 assays96 assays
No related Items
#34112652 2021/06/10 To Up
A young man with shortness of breath.
Michael Blank, Oliver Collas, Hassan Hirji1 g 1 G25 mg1 mg100 mg 100ul100 mg1 g5 mg10 mg10 mg
No related Items
#34097856 2021/06/04 To Up
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety of therapeutic versus prophylactic anticoagulation in this population.
Renato D Lopes, Pedro Gabriel Melo de Barros E Silva, Remo H M Furtado, Ariane Vieira Scarlatelli Macedo, Bruna Bronhara, Lucas Petri Damiani, Lilian Mazza Barbosa, JÃºlia de Aveiro Morata, Eduardo Ramacciotti, Priscilla de Aquino Martins, Aryadne Lyrio de Oliveira, Vinicius Santana Nunes, Luiz Eduardo Fonteles Ritt, Ana Thereza Rocha, Lucas Tramujas, Sueli V Santos, Dario Rafael Abregu Diaz, Lorena Souza Viana, LÃvia Maria Garcia Melro, Mariana Silveira de AlcÃ¢ntara Chaud, EstÃªvÃ£o Lanna Figueiredo, Fernando Carvalho Neuenschwander, Marianna Deway Andrade Dracoulakis, Rodolfo Godinho Souza Dourado Lima, Vicente CÃ©s de Souza Dantas, Anne Cristine Silva Fernandes, OtÃ¡vio Celso Eluf Gebara, Mauro Esteves Hernandes, Diego Aparecido Rios Queiroz, Viviane C Veiga, Manoel Fernandes Canesin, Leonardo Meira de Faria, Gilson Soares Feitosa-Filho, Marcelo Basso Gazzana, IdelzuÃta Leandro Liporace, Aline de Oliveira Twardowsky, Lilia Nigro Maia, FlÃ¡via Ribeiro Machado, Alexandre de Matos Soeiro, Germano EmÃlio ConceiÃ§Ã£o-Souza, Luciana Armaganijan, PatrÃcia O GuimarÃ£es, Regis G Rosa, Luciano C P Azevedo, John H Alexander, Alvaro Avezum, Alexandre B Cavalcanti, Otavio Berwanger,
1794 related Products with: Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.1 ml25 mg1 module1 module100 μg100ul50ul (0.45mg/ml)100ug/vial
No related Items
#33957960 2021/05/07 To Up
Alpha 2-antiplasmin deficiency in a Sudanese child: a case report.The plasma serine protease inhibitor alpha 2-antiplasmin (Î±-AP, otherwise known as Î±-plasmin inhibitor) is a rapid-acting plasmin inhibitor recently found in human plasma, which seems to have a significant role in the regulation of in vivo fibrinolysis. Congenital deficiency of Î±-AP is extremely uncommon.
Bashir Abdrhman Bashir Mohammed100 μg1mg100ug Lyophilized100 μg
#33924175 2021/04/20 To Up
Antithrombin and Its Role in Host Defense and Inflammation.Antithrombin (AT) is a natural anticoagulant that interacts with activated proteases of the coagulation system and with heparan sulfate proteoglycans (HSPG) on the surface of cells. The protein, which is synthesized in the liver, is also essential to confer the effects of therapeutic heparin. However, AT levels drop in systemic inflammatory diseases. The reason for this decline is consumption by the coagulation system but also by immunological processes. Aside from the primarily known anticoagulant effects, AT elicits distinct anti-inflammatory signaling responses. It binds to structures of the glycocalyx (syndecan-4) and further modulates the inflammatory response of endothelial cells and leukocytes by interacting with surface receptors. Additionally, AT exerts direct antimicrobial effects: depending on AT glycosylation it can bind to and perforate bacterial cell walls. Peptide fragments derived from proteolytic degradation of AT exert antibacterial properties. Despite these promising characteristics, therapeutic supplementation in inflammatory conditions has not proven to be effective in randomized control trials. Nevertheless, new insights provided by subgroup analyses and retrospective trials suggest that a recommendation be made to identify the patient population that would benefit most from AT substitution. Recent experiment findings place the role of various AT isoforms in the spotlight. This review provides an overview of new insights into a supposedly well-known molecule.
Christine SchlÃ¶mmer, Anna Brandtner, Mirjam Bachler50 ug 50 ug 50 ug 25 mg2.5 mg1000 tests8 Sample Kit200ul200ul100 mg4 Arrays/Slide10 mg
#33802928 2021/03/17 To Up
Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y could serve as components of dual anti-platelet therapy. We have found that a selective A agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine (HE-NECA) improved the anti-thrombotic properties of either cangrelor or prasugrel in the model of ferric chloride-induced experimental thrombosis in mice. Importantly, HE-NECA was effective not only when applied in bolus as other AR agonists in the up-to-date published studies, but also when given chronically. In vitro thrombus formation under flow conditions revealed that HE-NECA enhanced the ability of P2Y inhibitors to decrease fibrinogen content in thrombi, possibly resulting in their lower stability. Adenosine receptor agonists possess a certain hypotensive effect and an ability to increase the blood-brain barrier permeability. Therefore, the effects of anti-thrombotic doses of HE-NECA on blood pressure and the blood-brain barrier permeability in mice were tested. HE-NECA applied in bolus caused a significant hypotension in mice, but the effect was much lower when the substance was given in doses corresponding to that obtained by chronic administration. At the same time, no significant effect of HE-NECA was observed on the blood-brain barrier. We conclude that chronic administration of the A agonist can be considered a potential component of a dual antithrombotic therapy. However, due to the hypotensive effect of the substances, dosage and administration must be elaborated to minimize the side-effects. The total number of animals used in the experiments was 146.
Dawid Polak, Marcin Talar, Nina Wolska, Dagmara W Wojkowska, Kamil Karolczak, Karol Kramkowski, Tomasz A Bonda, Cezary Watala, Tomasz Przygodzki
1608 related Products with: Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.100ug100 μg100ug Lyophilized100ug100 μg100ug Lyophilized100ug Lyophilized100 μg100ug100 μg
#33769995 // To Up
Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.The preferred assay for measuring and adjusting unfractionated heparin (UFH) infusion to achieve optimal outcomes during extracorporeal membrane oxygenation (ECMO) is not well established. This retrospective cohort study explored safety and efficacy outcome differences between anti-factor Xa (anti-Xa) and activated partial thromboplastin time (aPTT) for UFH in adult venoarterial ECMO. Forty-one patients were included and analyzed. The UFH rate at first goal and time to goal were both higher in the aPTT versus anti-Xa cohort but did not achieve statistical significance (12.14 vs. 9.58 unit/kg/hour (p = 0.29), 20.22 vs. 12.05 hours (p = 0.11)). The aPTT cohort was in target goals 35.0% of the time versus 47.7% in the anti-Xa cohort (p = 0.13), above goal 41.0% vs. 17.3% (p = 0.02), and below-goal 24.0% versus 35.0% of the time (p = 0.34). Minimum heparin rates in the aPTT cohort were 6.28 vs. 3.33 unit/kg/hour in the anti-Xa cohort (p = 0.07), and the maximum UFH rate was 18.77 unit/kg/hour vs. 15.48 unit/kg/hour (p = 0.10). Our findings suggest that aPTT monitoring may result in a delay to target attainment, higher UFH rates, and overall exposure.
Caitlin E Kulig, Kendra J Schomer, Hugh B Black, William E Dager
1854 related Products with: Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.100.00 ug100.00 ug1100ul4 Membranes/Box100.00 ug100.00 ug20 20 100 μg100.00 ug0.1ml (1mg/ml)
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia